In cohort 6, subjects aged two years old at the time of treatment showed a mean expression of 93.87% of normal dystrophin ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new ...

Shares of Sarepta Therapeutics advanced after the company said it has received the go-ahead from U.K. regulators to keep dosing in a study of its Elevidys treatment for Duchenne muscular dystrophy.

Sarepta Therapeutics (NASDAQ:SRPT) and its partner Roche (OTCQX:RHHBY) received a 'go ahead' from the regulatory body in U.K.

Sarepta Therapeutics shares were higher after J.P. Morgan reduced its December 2025 price target to $84 from $169 and maintained its overweight rating. The stock was up 4% to $39.55 Tuesday and is ...

--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today presented new data from Part 2 of the EMBARK study that continue to support ...

Taking center stage at the American Society of Gene and Cell Therapy meeting was the first-ever reported case of a ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known ...

A local favorite in the mental health community is expanding its services to offer something truly special for the residents of Prince George's County and beyond. McGuire Therapeutic Services is proud ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results , with sales up 80.2% year on year to $744.9 ...